Immedica announces publication of 2023 Business Review and Annual & Sustainability Report
Stockholm, April 26, 2024 – Immedica is proud to announce the release of our Business Review and Annual & Sustainability Report for the year 2023. This year marks the most successful period in our history since the company's establishment in 2018, highlighting our substantial progress and achievements.
In 2023, Immedica strengthened its position as an emerging leader in the rare disease sector across Europe and the MENA region. Through strategic initiatives and a dedicated focus on our core mission, we have taken significant strides toward becoming a frontrunner in this important field.
“With exceptional entrepreneurship, solid functional skill sets and capabilities fostered by a strong ‘can-do’ attitude, the team have time after time proven that we can overcome any obstacle together and achieve great things.” Anders Edvell, CEO
Our 2023 report not only reflects on these achievements but also outlines our continued commitment to sustainability. It underscores our dedication to making a lasting impact on patients' lives through innovative therapies.
To learn more about Immedica's accomplishments in 2023, please visit our website at www.immedica.com.
About Immedica
Immedica is a pharmaceutical company, headquartered in Stockholm, Sweden, focused on the commercialization of medicines for rare diseases and specialty care products. Immedica’s capabilities cover marketing and sales, compliance, pharmacovigilance, quality assurance, regulatory, medical affairs and market access, as well as a global distribution network serving patients in more than 50 countries. Immedica is fully dedicated to helping those living with diseases which have a large unmet medical need. Immedica’s therapeutic areas are within genetic & metabolic diseases, hematology & oncology and specialty care.
Immedica was founded in 2018 by the investment company Impilo and Buy-in-Management. Today Immedica employs more than 100 people across Europe and the Middle East.
For more information visit www.immedica.com
Immedica contact:
Linda Holmström
Head of Communication
[email protected]
+ 46 708 73 40 95
Immedica Pharma AB
Solnavägen 3H
SE-113 63 Stockholm